본문 바로가기
KERD
논문KCI 등재

가와사끼병에서 정맥용 면역글로불린 치료 반응 예측의 한계

Limitation of Prediction on Intravenous Immunoglobulin Responsiveness in Kawasaki Disease

한지윤|오진희|한지환|이경일|김성구|강진한|이준성|임정우
대한소아감염학회 (The Korean Society of Pediatric Infectious Diseases)|2010.12|Pediatric Infection and Vaccine|제17권 제2호|pp. 169-176

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

Treatment responseKawasaki diseaseMucocutaneous Lymph Node SyndromeLaboratory parametersCoronary artery lesionIntravenous Immunoglobulin

초록

목 적 : 가와사끼병 환자들에서 정맥용 면역글로불린(intravenous immunoglobulin, IVIG) 불응군의 예측지표를 두 대조군을 사용하여 연구하였다. 방 법 : 가톨릭대학교 대전성모병원에서 IVIG 2 g/kg 로 치료한 229명의 가와사끼병 환자들을 대상으로 하였다. 23명 IVIG 불응군(IVIG 투여 후에도 24시간 이상발열이 지속)과, 첫번째 206명의 IVIG 반응군 및 두번째 연령과 치료 전 발열일을 일치시킨 46명의 대조군에대해 임상적, 검사실 소견을 비교하였다. 결 과:인구학적, 임상적 소견은 IVIG 불응군과 반응군이 유사하였다. 검사실 소견에서, 두 가지 연구 모두에서 IVIG 불응군은 반응군에 비해서 중성구 분획, CRP,AST, ALT 그리고, LDH는 유의하게 상승되었고, 림프구 분획, 총 단백질, 알부민, 혈소판 수, 그리고 총 콜레스테롤은 유의하게 저하되어 있었다(단변수분석). 그러나, 다변수분석에서 첫번째 연구에서 높은 중성구 분획(cutoff value, >77%, 민감도 68.4%, 특이도 79.5%)과 낮은 총 콜레스테롤(<124 mg/dL, 민감도 79%, 특이도 70.5%)이, 두번째 연구에서는 알부민(<3.6 g/dL, 민감도 73.7%, 특이도 60%)만이 불응군의 예측 지표로나타났다. 결 론 : 가와사끼병에서 염증의 중증도는 발병 시에 상승되거나 저하된 검사실 소견에 반영된다. 이러한 검사실 지표에 대한 다변수분석은 환아수, 연령 및 발열 기간등의 인자에 의해서 영향을 받으므로, 관상동맥병변의위험이 큰 가와사끼병 환자들을 찾기 위한 다른 접근 방법이 필요하다.

Abstract

Purpose : We aimed to evaluate predictive parameters for non-response to intravenous immunoglobulin (IVIG) in patients with Kawasaki disease (KD) before IVIG use using two controls. Methods : We evaluated 229 consecutive KD patients who were treated with 2 g/kg of IVIG at a single center. Those who had persistent fever >24 hours after IVIG infusion made up the 23 IVIG non-responders; the first control included a total 206 defervesced cases and the second control included 46 cases that were matched for age and pre-treatment fever duration to non-responders. Results : Demographic and clinical characteristics were similar in IVIG non-responders and responders at presentation. As for laboratory findings, the neutrophil differential, CRP, AST, ALT, and LDH were higher, and lymphocyte differential,total protein, albumin, platelet count, and total cholesterol were significantly lower in IVIG non-responders compared to responders by univariate analysis in both study designs. However in multivariate analysis, non-responders showed a significantly higher neutrophil differential (cutoff value, >77%, sensitivity 68.4% and specificity 79.5%) and lower cholesterol (<124mg/dL, sensitivity 79% and specificity 70.5%). Whereas plasma albumin (<3.6 g/dL, sensitivity 73.7% and specificity 60%)was the sole laboratory parameter of non-responders in the second study design. Conclusion : Severity of inflammation in KD was reflected by higher or lower laboratory values at presentation. Because the multivariate analysis for these indices may be influenced by some confounding factors, including the numbers of patients of different ages and fever duration, other assessment modalities are needed for KD patients with the greatest risk of coronary artery lesions.

참고문헌 (32)

  1. Kawasaki T, "Kawasaki disease. Historical background and current issues", Prog Clin Biol Res, 250, pp.1~4 (1987)
  2. Newburger JW, "Diagnosis, treatment, and longterm management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association", Pediatrics, 114, pp.1708~1733 (2004)
  3. Burgner D, "Kawasaki disease: what is the epidemiology telling us about the aetiology?", Int J Infec Dis, 9, pp.185~194 (2005)
  4. Lee KY, "Kawasaki disease may be a hyperimmune reaction of genetically-susceptible children to variants of normal environmental flora", Med Hypotheses, 69, pp.642~651 (2007)
  5. Furusho K, "Shinomiya K, Hayashidera T, et al. High dose intravenous gamma globulin therapy for Kawasaki syndrome", Lancet, 2, pp.1055~1058 (1984)
  6. Newberger JW, "A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of Kawasaki syndrome", N Engl J Med, 324, pp.1633~1639 (1991)
  7. Wright DA, "Treatment of immunoglobulin-resistant Kawasaki disease with pulsed doses of corticosteroids", J Pediatr, 128, pp.146~149 (1996)
  8. Burns JC, "Intravenous gamma-globulin treatment and retreatment in Kawasaki disease: US", Canadian Kawasaki Syndrome Study Group, 1998, pp.17, 1144~1148
  9. Burns JC, "Infliximab treatment for refractory Kawasaki syndrome", J Pediatr, 146, pp.662~667 (2005)
  10. Nakano H, "Scoring method for identifying patients with Kawasaki disease at high risk coronary artery aneurysms", Am J Cardiol, 58, pp.739~742 (1986)
  11. Koren G, "Kawasaki disease: review of risk factors for coronary aneurysms", J Pediatr, 108, pp.388~392 (1986)
  12. Beiser AS, "Newburger JW. A predictive instrument for coronary artery aneuryms in Kawasaki disease", Am J Cardiol, 81, pp.1116~1120 (1998)
  13. Harada K, "Intravenous gamma-globulin treatment in Kawasaki disease", Acta Pediatr Jpn, 33, pp.805~810 (1991)
  14. McCrindle BW, "Coronary artery involvement in children with Kawasaki disease; risk factors from analysis of serial normalized measurements", Circulation, 116, pp.174~179 (2007)
  15. Mori M, "Predictors of coronary artery lesions after intravenous -globulin treatment in Kawasaki γ disease", J Pediatr, 137, pp.177~180 (2000)
  16. Fukunishi M, "Prediction of nonresponsiveness to intravenous high-dose γ-globulin therapy in patients with Kawasaki disease at onset", J Pediatr, 137, pp.172~176 (2000)
  17. Durongpisitkul K, "Immunoglobulin failure and retreatment in Kawasaki diseasae", Pediatr Cardiol, 24, pp.145~148 (2003)
  18. Egami K, "Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease", J Pediatr, 149, pp.237~240 (2006)
  19. Kobayashi T, "Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease", Circulation, 113, pp.2606~2612 (2006)
  20. Sano T, "Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment", Eur J Pediatr, 166, pp.131~137 (2007)
  21. Uehara R, "Analysis of potential risk factors associated with nonresponse to initial intravenous immunoglobulin treatment among Kawasaki disease patients in Japan", Pediatr Infect Dis J, 27, pp.155~160 (2008)
  22. Tremoulet AH, "Resistance to intravenous immunoglobulin in children with Kawasaki disease", J Pediatr, 153, pp.117~121 (2008)
  23. Research Committee on Kawasaki disease, "Report of Subcommittee on Standardization of Diagnostic Criteria and Reporting of Coronary Artery Lesions in Kawasaki disease", Ministry of Health and Welfare, ~ (1984)
  24. Lee KY, "Features of Kawasaki disease at the extreams of age", J Paediatr Child Health, 42, pp.423~427 (2006)
  25. Lee Kyung Yil, "Inflammatory Processes in Kawasaki Disease Reach their Peak at the Sixth Day of Fever Onset: Laboratory Profiles According to Duration of Fever", Journal of Korean Medical Science, 19(4), pp.501~504 (2004), 대한의학회
  26. Checchia PA, "Circulating cardiac troponin I levels in Kawasaki disease", Pediatr Cardiol, 22, pp.102~106 (2001)
  27. Kelley-Hedgepeth A, "Ethnic differences in C-reactive protein concentration", Clin Chem, 54, pp.1027~1037 (2008)
  28. Sakata K, "A randomized prospective study on the use of 2 g-IVIG or 1 g-IVIG as therapy for Kawasaki disease", Eur J Pediatr, 16, pp.565~571 (2007)
  29. Lee KY, "High-dose intravenous immunoglobulin downregulates the activated levels of inflammatory indices except erythrocyte sedimentation rate in acute stage of Kawasaki disease", J Trop Pediatr, 51, pp.98~101 (2005)
  30. Hwang JY, "Assessment of intravenous immunoglobulin non-responders in Kawasaki disease", Arch Dis Child (2010)
  31. Kushner HI, "Kawasaki disease in India: increasing awareness or increased incidence?", Perspect Biol Med, 52, pp.17~29 (2009)
  32. Du ZD, "Epidemiologic study on Kawasaki disease in Beijing from 2000 through 2004", Pediatr Infect Dis J, 26, pp.449~451 (2007)

관련 논문AI추천

가와사끼병에서 정맥용 면역글로불린 불응군의 특성고용민, 국동혁, 김동언, 이경일, 이근영, 이준성대한소아감염학회 · Pediatric Infection and Vaccine2008 · 제15권 제2호한국인에서 면역글로불린-저항성 가와사키병 환자의 예측김기환, 김동수, 박청수, 최명현대한소아감염학회 · Pediatric Infection and Vaccine2014 · 제21권 제1호발열 5일 이전과 이후에 방문한 가와사키병 환자의 급성기반응물질 결과 비교강창우, 김동훈, 김태윤, 도현정, 이상봉, 이수훈, 정진희대한소아응급의학회 · 대한소아응급의학회지2019 · 제6권 제1호C-reactive Protein and Erythrocyte Sedimentation Rate Discrepancies and Variations after Intravenous Immunoglobulin Therapy in Kawasaki Disease손세정, 이윤숙, 이지현, 홍영미대한소아감염학회 · Pediatric Infection and Vaccine2016 · 제23권 제1호농뇨 동반 가와사키병의 임상적 특징김효진, 이수영, 이주영, 최의윤대한소아감염학회 · Pediatric Infection and Vaccine2017 · 제24권 제3호정맥용 면역 글로불린 무반응성 가와사끼병 2례김현부, 조병수, 차성호대한소아감염학회 · Pediatric Infection and Vaccine1998 · 제5권 제1호

이 간행물의 다른 논문 (13건)

소아 요로감염의 원인균주별 임상양상과 항생제 내성률 : 대장균과 비대장균의 비교배이영, 이수영, 강진한, 정대철pp. 67-73소아 요로감염 진단에 있어 신속배양검사(Uricult Trio)의 유용성에 관한 연구이택진, 차성호, 김은진, 장진근, 이진pp. 74-82소아 환자에서 다균혈증에 대한 임상적 고찰김정민, 박혜진, 김기환, 김동수pp. 83-90소아 재발성 중이염의 위험인자에 대한 연구권영란, 차성호, 김은진, 장원녕, 이진, 송강훈, 장진근pp. 91-100소아에 있어서 C-반응성 단백의 모세혈 및 정맥혈 검사의 비교평가김순기, 홍영진, 진지훈, 손병관, 정수호pp. 101-107
원문 보기